Navigation Links
Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Date:3/25/2009

CRANBURY, N.J., March 25 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the issuance on March 10, 2009 of United States Patent No. 7,501,439, titled "Tartrate Salt of Isofagomine and Methods of Use." The patent covers the tartrate salt form of isofagomine, the active ingredient in the Company's investigational drug Plicera(TM) (afegostat tartrate), and its use for the treatment of Gaucher disease. The patent will expire in 2027.

John F. Crowley, President and CEO of Amicus, commented, "The issuance of this patent further strengthens our protection in the United States for Plicera in Gaucher and is one example of our ongoing efforts to establish a comprehensive intellectual property portfolio for our development programs and our pharmacological chaperone technology platform."

Plicera is currently being studied in an ongoing Phase 2 study in patients naive to enzyme replacement therapy. This six-month study is designed to evaluate safety and to demonstrate trends of efficacy, as measured by the standard endpoints in Gaucher disease. Amicus previously reported that enrollment has been completed for the study and the Company expects the results to be available in the third quarter of 2009.

Amicus is developing Plicera as part of a strategic collaboration with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the collaboration, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic d
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... Dec. 1 Sleep Solutions®, Inc...or home testing and evaluation of sleep-disordered...assett, M.D., as its chief executive officer. Has...are, during its growth from a $250 million healthc...eader in total population health, and its subseque...
(Date:12/1/2009)....J., Dec. 1 Siemens Hearing Instr...ding global manufacturer of hearing instruments, a...nternational,s Sound Beginnings program. The allia..., As part of the renewed partnership, Siemens is e...ree hearing instruments to both children and young...
(Date:12/1/2009)..., China, Dec. 1 /PRNewswire-Asia-FirstCall/ -- Tia... a manufacturer and supplier of,modernized traditi...ina, today,announced that it has received approval...ion (SFDA) to produce Pediatric Fever and Cough Or...val number Z20093060) and Antibacterial,and Anti-i...
Breaking Medicine Technology:Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 2Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 3Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 3Pharmacist Injects Cure for Ailing Businesses 62172 1Pharmacist Injects Cure for Ailing Businesses 62172 2Kansas City Prepares for Largest Free Health Clinic 62169 1Kansas City Prepares for Largest Free Health Clinic 62169 2FDAs Woodcock Discusses Pain Management and Drug Safety in Nov 26 2009 Issue of The New England Journal of Medicine 62164 1
... track to have Phase 3 data available by the sprin...zation applications expected by the .... 28 Human Genome,Sciences, Inc. (Nasdaq: HGSI )...and initial dosing ahead of schedule in ACHIEVE 1,...ron(R) (albinterferon alfa-2b) in,combination with...
...IND Meeting Scheduled For August 29, 2007, STOCKH...al AB (http://www.omxgroup.com, ticker: DIAM B; ...l announced today that NP2, the company,s first dr...system (NTDDS) gene therapy,platform, will be the ...eting with the U.S. Food and Drug Administration o...
Other Medicine Technology:Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule 2Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule 3Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule 4Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule 5Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain 2Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain 3Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain 4Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain 5
(Date:12/1/2009)... , , SAN DIEGO, Dec. 1 /PRNewswire-Fi...ied supplier of Farming, Nursery and Wellness prod...ing agreement with Southern California Micro-Lendi...m ). ,, Yan Skwara, CEO of US Farms, Inc. stat... partnership with Angels in Action utilizing our A...
(Date:12/1/2009)... , , BRUSSELS, December 1 /PRNewswir...perts Agree That Adapting Food,Production and Mode...ons , Prof. John Beddington, Chief Scient...ll agricultural policy must be founded on science ...cientific advisor with the,responsibility to look ...
(Date:12/1/2009)... Some become so worried about what might happen t..., , TUESDAY, Dec. 1 (HealthDay News) -- ...into depression, a new study suggests. , "Anxie...udy author Andres Viana, a graduate student in psy...ose with anxiety sensitivity are afraid of their a...
(Date:12/1/2009)... Radiation exposures in younger women may up chan... Dec. 1 (HealthDay News) -- Mammograms may actuall...k women, a new study suggests. , Dutch research...r examining the effect of low-dose radiation expos...mutation boosting breast cancer risk and two looki...
(Date:12/1/2009)... , Research released in the December 2009 issue o...ermine whether the survival improvement among pati... the last two decades as reported in controlled cl...sis of over 100,000 patients with stage IV non-sma... SEER database to evaluate trends in survival betw...
Breaking Medicine News(10 mins):Health News:US Farms, Inc. Announces Marketing Agreement With Micro Lending Institution Angels In Action 2Health News:US Farms, Inc. Announces Marketing Agreement With Micro Lending Institution Angels In Action 3Health News:Food Security to be the Top Issue for EU's Science Chief 2Health News:Fear of Anxiety May Lead to Depression 2Health News:Mammograms May Boost Cancer Risk in High-Risk Women 2
... increase your chance of having colorectal cancer/... Cancer Institute. Colon and rectum together ...cancer is also called colorectal cancer. Cancer of...tive Investigation into Cancer and Nutrition have ...
...patients with the help of seroquel is effective//,... severe disabling mental illness. Some of the symp...seen or heard, feelings of being persecuted, becom...ough most schizophrenic patients are not aggressiv...
... why the diabetes drug thiazolidinediones (TZDs) c...ity of Utah had found that the drug TZDs activates...or-activated receptor gamma (PPAR). This is situat...nerally used to lower blood sugar levels and lipid...
...tions of the gum may increase the risk of the Alzh...rly in life. According to a research study th...on International Conference on Prevention of Demen...nd slowly destroys them. The main symptoms of the ...
...p that can keep people have a long life//. An...he benefits of having friends do affect the health...t life expectancy can get significantly increased.... 70 years and above. Researchers had monitored fac...
...ranelate to be used for treating patients with ost...escribing the drug it is important to observe the ...in the British Medical Journal has said that the d...recent studies on the drug had shown the drug to b...
Other Medicine News:
...nd ULTIMA PLUS are the "ultimate finishing systems...se new products expand the finishing room proficie...ures at a very reasonable price. The ULTIMA Series...creen, Topcons precision 3D frame tracing, safety ...
Topcon FR-2 Frame Reader
...it color mapping software system enhances clinical...ull color corneal maps. The system offers an enlar...s, refractive and keratometric data, and periphera...tion of subclinical keratoconus as well as pre and...
TOPCON PD-5 Pupilometer
Medicine Products: